Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02082210
Title A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

hepatocellular carcinoma

Advanced Solid Tumor

renal cell carcinoma

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Emibetuzumab + Ramucirumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Massachusetts General Hospital Boston Massachusetts 02114-3117 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Tennessee Oncology PLLC Nashville Tennessee 37203 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field